Clinical Scorecard: The Role of the Glucose-6-Phosphatase System in Cancer: Implications for Endoplasmic Reticulum Glucose-6-Phosphate Dynamics, Stem Cell Properties, Immune Evasion, and Treatment Sensitivity

At a Glance

Key Highlights

• G6Pase system components are emerging as biomarkers and therapeutic targets in cancer.
• Elevated G6Pase activity is associated with aggressive cancer phenotypes.
• G6P handling in the endoplasmic reticulum influences tumor behavior.
• Pharmacological interference with G6P transporters affects glioma cell survival and migration.
• The G6Pase system operates as a metabolic rheostat in cancer cells.

Guideline-Based Recommendations

Diagnosis

• Consider G6Pase system components as potential biomarkers in cancer.

Management

• Investigate therapeutic targeting of the G6Pase system in preclinical settings.

Monitoring & Follow-up

• Monitor G6Pase system activity as a potential indicator of tumor aggressiveness.

Risks

• Loss of G6PC or SLC37A4 function may lead to metabolic disruptions.

Patient & Prescribing Data

Patients with cancers exhibiting altered G6P metabolism.

Therapeutic opportunities targeting the G6Pase system are largely preclinical.

Clinical Best Practices

• Evaluate the role of G6Pase system in tumor metabolism during cancer treatment planning.
• Consider the implications of G6P dynamics in the context of cancer stem cell properties.

Related Resources & Content

• Source Article